Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

21. Vosevi - for the treatment of chronic hepatitis C virus (HCV) infection

Vosevi - for the treatment of chronic hepatitis C virus (HCV) infection Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1

Health Canada - Drug and Health Product Register2018

22. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.

L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. BACKGROUND: Hepatic encephalopathy is a common complication of cirrhosis and has high associated morbidity and mortality. The condition is classified as overt if it is clinically apparent or minimal if only evident though psychometric testing. The exact pathogenesis of this syndrome is unknown although ammonia is thought to play a key role. L-ornithine L-aspartate has ammonia-lowering (...) properties and may, therefore, benefit people with cirrhosis and hepatic encephalopathy. OBJECTIVES: To evaluate the beneficial and harmful effects of L-ornithine L-aspartate versus placebo, no intervention, or other active interventions in people with cirrhosis and hepatic encephalopathy. SEARCH METHODS: We undertook electronic searches of The Cochrane Hepato-Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, Embase, LILACS and Science Citation Index Expanded to December 2017 and manual

Cochrane2018

23. Treatment for hepatitis C virus-associated mixed cryoglobulinaemia.

Treatment for hepatitis C virus-associated mixed cryoglobulinaemia. BACKGROUND: Hepatitis C virus (HCV)-associated mixed cryoglobulinaemia is the manifestation of an inflammation of small and medium-sized vessels produced by a pathogenic IgM with rheumatoid factor activity generated by an expansion of B-cells. The immune complexes formed precipitate mainly in the skin, joints, kidneys or peripheral nerve fibres. Current therapeutic approaches are aimed at elimination of HCV infection, removal (...) AND ANALYSIS: Two authors independently assessed the retrieved titles and abstracts. Authors of included studies were contacted to obtain missing information. Statistical analyses were performed using random effects models and results expressed as risk ratio (RR) or mean difference (MD) with 95% confidence interval (CI). The planned primary outcomes were kidney disease, skin vasculitis, musculoskeletal symptoms, peripheral joint arthralgia, peripheral neuropathies, liver involvement, interstitial lung

Cochrane2018

24. Obeticholic acid (Ocaliva): risk of serious liver injury in patients with pre-existing moderate or severe hepatic impairment; reminder to adjust dosing according to liver function monitoring

Obeticholic acid (Ocaliva): risk of serious liver injury in patients with pre-existing moderate or severe hepatic impairment; reminder to adjust dosing according to liver function monitoring Obeticholic acid (Ocaliva▼): risk of serious liver injury in patients with pre-existing moderate or severe hepatic impairment; reminder to adjust dosing according to liver function monitoring - GOV.UK GOV.UK uses cookies to make the site simpler. Search Obeticholic acid (Ocaliva▼): risk of serious liver (...) injury in patients with pre-existing moderate or severe hepatic impairment; reminder to adjust dosing according to liver function monitoring We are aware of reports of serious liver injuries and deaths in patients with primary biliary cholangitis with pre-existing moderate or severe liver impairment who were not adequately dose-adjusted. Follow dose reduction and monitoring advice in these patients to reduce the risk of serious liver injury. Published 24 April 2018 From: Therapeutic area: Contents

MHRA Drug Safety Update2018

25. Chronic Hepatitis B Infection: A Review.

Chronic Hepatitis B Infection: A Review. Importance: More than 240 million individuals worldwide are infected with chronic hepatitis B virus (HBV). Among individuals with chronic HBV infection who are untreated, 15% to 40% progress to cirrhosis, which may lead to liver failure and liver cancer. Observations: Pegylated interferon and nucleos(t)ide analogues (lamivudine, adefovir, entecavir, tenofovir disoproxil, and tenofovir alafenamide) suppress HBV DNA replication and improve liver (...) inflammation and fibrosis. Long-term viral suppression is associated with regression of liver fibrosis and reduced risk of hepatocellular carcinoma in cohort studies. The cure (defined as hepatitis B surface antigen loss with undetectable HBV DNA) rates after treatment remain low (3%-7% with pegylated interferon and 1%-12% with nucleos[t]ide analogue therapy). Pegylated interferon therapy can be completed in 48 weeks and is not associated with the development of resistance; however, its use is limited

JAMA2018

26. Defibrotide (Defitelio) - hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS)

Defibrotide (Defitelio) - hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity

Health Canada - Drug and Health Product Register2018

27. Two drug treatments for severe alcoholic hepatitis do not improve survival rates

Two drug treatments for severe alcoholic hepatitis do not improve survival rates NIHR DC | Signal - Two drug treatments for severe alcoholic hepatitis do not improve survival rates Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Two drug treatments for severe alcoholic hepatitis do not improve survival rates Published on 23 April 2015 This NIHR funded trial found that neither prednisolone nor pentoxifylline improved mortality for people with severe alcoholic hepatitis (...) . No differences were found in mortality at 28 or 90 days, or in the need for liver transplant at one year. Overall mortality was high. Nearly three in ten people died before 90 days and more than half (56%) at one year. This shows that other new treatments are needed and more needs to be done to encourage complete abstinence from alcohol following severe alcoholic hepatitis. Why was this study needed? UK estimates from 2009 show a quarter of adults drink in a hazardous or harmful way. People with prolonged

NIHR Dissemination Centre2018

28. Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs

Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs NIHR DC | Signal - Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs Dissemination Centre Discover Portal NIHR DC Discover Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs Published on 5 December 2017 A combination of providing clean needles and syringes and offering (...) safer oral therapy, such as methadone, reduced the predicted risk of becoming infected with hepatitis C virus by 71%. Providing both services to people who inject drugs was likely to be cost-effective and has the potential to be cost-saving in some parts of the UK, depending on the size of the local population of people who inject drugs and underlying rates of infection. Current services are estimated to save up to £54 million in costs of treating hepatitis C infection. This is in addition

NIHR Dissemination Centre2018

29. Tenofovir reduces mother-to-child hepatitis B transmission

Tenofovir reduces mother-to-child hepatitis B transmission NIHR DC | Signal - Tenofovir reduces mother-to-child hepatitis B transmission Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Tenofovir reduces mother-to-child hepatitis B transmission Published on 25 July 2017 Giving pregnant women with hepatitis B the drug tenofovir reduced the likelihood of passing the infection on to their baby by about 80% and did not have any adverse impact on mother or child. Hepatitis B often (...) doesn't cause any obvious symptoms in adults and typically passes in a few months without treatment, but in children it often persists for years and may cause progressive liver damage with cirrhosis and increased risk of liver cancer. Babies can get the infection from their mother during birth. The findings of this systematic review support current NICE recommendations that pregnant women with active hepatitis B infection are treated in the third trimester using the drug tenofovir and at risk babies

NIHR Dissemination Centre2018

30. Diagnosis of Minimal Hepatic Encephalopathy: A Systematic Review of Point-of-Care Diagnostic Tests

Diagnosis of Minimal Hepatic Encephalopathy: A Systematic Review of Point-of-Care Diagnostic Tests 29533396 2018 04 09 1572-0241 113 4 2018 Apr The American journal of gastroenterology Am. J. Gastroenterol. Diagnosis of Minimal Hepatic Encephalopathy: A Systematic Review of Point-of-Care Diagnostic Tests. 529-538 10.1038/ajg.2018.6 Minimal hepatic encephalopathy (HE) is common, characterized by deficits in reaction time and executive function, and strongly associated with disability (...) ;12(8):1384-1389.e2 24362049 Hepatology. 2017 Jul;66(1):198-208 28271528 Ann Intern Med. 2011 Oct 18;155(8):529-36 22007046 Dig Dis Sci. 2010 Aug;55(8):2381-90 20508990 Hepatology. 2014 Aug;60(2):715-35 25042402 Gastroenterology. 2008 Nov;135(5):1591-1600.e1 18723018 Liver Int. 2017 Dec;37(12 ):1843-1851 28618192 Clin Gastroenterol Hepatol. 2016 Aug;14 (8):1181-1188.e2 27085758 Saudi J Gastroenterol. 2013 Jan-Feb;19(1):40-4 23319037 J Hepatol. 2001 May;34(5):768-73 11434627 Am J Transplant. 2014

EvidenceUpdates2018

31. Hepatitis C: sofosbuvir + velpatasvir (Epclusa) represents an advance for some patients

Hepatitis C: sofosbuvir + velpatasvir (Epclusa) represents an advance for some patients Prescrire IN ENGLISH - Spotlight ''Hepatitis C: sofosbuvir + velpatasvir (Epclusa°) represents an advance for some patients'', 1 April 2018 {1} {1} {1} | | > > > Hepatitis C: sofosbuvir + velpatasvir (Epclusa°) represents an advance for some patients Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |    (...) |   |   |  Spotlight Hepatitis C: sofosbuvir + velpatasvir (Epclusa°) represents an advance for some patients The combination sofosbuvir + velpatasvir (Epclusa°) offers a therapeutic advance in the treatment of hepatitis C, especially in patients infected by a genotype 2 virus. But the uncertainty surrounding its adverse effects is unacceptable. Hepatitis C can cause complications such as cirrhosis and liver cancer. Treatment depends on the virus genotype, the severity

Prescrire2018

34. Practice Advisory: Hepatitis B Prevention

Practice Advisory: Hepatitis B Prevention Practice Advisory: Hepatitis B Prevention - ACOG Menu ▼ Practice Advisory: Hepatitis B Prevention Page Navigation ▼ Share: Practice Advisory: Hepatitis B Prevention The Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP) have released updated guidance on preventing the transmission of hepatitis B virus (HBV) infection (1). A critical element of the strategy to eliminate HBV in the United States (...) is the prevention of perinatal transmission. The CDC and ACIP’s updated guidance reflects the best currently available evidence and select new or updated recommendations include the following: Pregnant women positive for hepatitis B surface antigen (HBsAg) should be tested for hepatitis B virus deoxyribonucleic acid (HBV DNA) to guide the use of antiviral medication to prevent perinatal transmission Persons with chronic liver disease* should be vaccinated against HBV The American Association for the Study

American College of Obstetricians and Gynecologists2018

35. Increase in hepatic and decrease in peripheral insulin clearance characterize abnormal temporal patterns of serum insulin in diabetic subjects

Increase in hepatic and decrease in peripheral insulin clearance characterize abnormal temporal patterns of serum insulin in diabetic subjects ARTICLE OPEN Increase in hepatic and decrease in peripheral insulin clearance characterize abnormal temporal patterns of serum insulin in diabetic subjects Kaoru Ohashi 1 , Masashi Fujii 1,2 , Shinsuke Uda 3 , Hiroyuki Kubota 3 , Hisako Komada 4 , Kazuhiko Sakaguchi 4 , Wataru Ogawa 4 and Shinya Kuroda 1,2,5 Insulin plays a central role in glucose (...) homeostasis, and impairment of insulin action causes glucose intolerance and leads to type 2 diabetes mellitus (T2DM). A decrease in the transient peak and sustained increase of circulating insulin following an infusion of glucose accompany T2DM pathogenesis. However, the mechanism underlying this abnormal temporal pattern of circulating insulin concentration remains unknown. Here we show that changes in opposite direction of hepatic and peripheral insulin clearance characterize this abnormal temporal

NPJ systems biology and applications2018 Full Text: Link to full Text with Trip Pro

36. Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B.

Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. BACKGROUND: Pregnant women with an elevated viral load of hepatitis B virus (HBV) have a risk of transmitting infection to their infants, despite the infants' receiving hepatitis B immune globulin. METHODS: In this multicenter, double-blind clinical trial performed in Thailand, we randomly assigned hepatitis B e antigen (HBeAg)-positive pregnant women with an alanine aminotransferase level of 60 IU or less per liter (...) to receive tenofovir disoproxil fumarate (TDF) or placebo from 28 weeks of gestation to 2 months post partum. Infants received hepatitis B immune globulin at birth and hepatitis B vaccine at birth and at 1, 2, 4, and 6 months. The primary end point was a hepatitis B surface antigen (HBsAg)-positive status in the infant, confirmed by the HBV DNA level at 6 months of age. We calculated that a sample of 328 women would provide the trial with 90% power to detect a difference of at least 9 percentage points

NEJM2018

37. Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis

Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis - Kruger - 2018 - Hepatology Communications - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search term Search Search term Search Original Article (...) Open Access Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA Gastrointestinal Unit, Massachusetts General Hospital and Harvard

Hepatology communications2018 Full Text: Link to full Text with Trip Pro

38. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.

Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. Background: Given the high mortality rate for patients with end-stage kidney disease receiving dialysis and the efficacy and safety of hepatitis C virus (HCV) treatments, discarded kidneys from HCV-infected donors may be a neglected public health resource. Objective: To determine the tolerability and feasibility of using direct-acting

Annals of Internal Medicine2018

39. Risk of hepatocellular carcinoma for patients treated with direct-acting antivirals: steps after hepatitis C virus eradication to achieve elimination

Risk of hepatocellular carcinoma for patients treated with direct-acting antivirals: steps after hepatitis C virus eradication to achieve elimination 29682622 2018 11 14 2415-1289 3 2018 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Risk of hepatocellular carcinoma for patients treated with direct-acting antivirals: steps after hepatitis C virus eradication to achieve elimination. 15 10.21037/tgh.2018.02.03 Lee Mei-Hsuan MH Institute of Clinical Medicine, National (...) Yang-Ming University, Taipei. eng Editorial Comment 2018 03 05 China Transl Gastroenterol Hepatol 101683450 2415-1289 Gastroenterology. 2017 Oct;153(4):996-1005.e1 28642197 JAMA. 2012 Dec 26;308(24):2584-93 23268517 J Viral Hepat. 2018 Mar;25(3):228-235 29053909 Epidemiol Rev. 2015;37:131-43 25600415 Gastroenterology. 2017 Mar;152(4):911-912 28161225 Hepatology. 2015 Aug;62(2):355-64 25716707 Sci Rep. 2017 Jun 16;7(1):3718 28623331 Gastroenterology. 2017 Oct;153(4):996-1005.e1 28642197 Hepatology

Translational gastroenterology and hepatology2018 Full Text: Link to full Text with Trip Pro

40. Sofosbuvir (Sovaldi) - for the treatment of chronic hepatitis C in adolescents

Sofosbuvir (Sovaldi) - for the treatment of chronic hepatitis C in adolescents Published 12 March 2018 Statement of Advice: sofosbuvir 400mg film-coated tablets (Sovaldi ® ) SMC No 1326/18 Gilead Sciences Ltd 9 February 2018 ADVICE: in the absence of a submission from the holder of the marketing authorisation sofosbuvir (Sovaldi ® ) is not recommended for use within NHS Scotland. Indication under review: In combination with other medicinal products for the treatment of chronic hepatitis C

Scottish Medicines Consortium2018